Silvia Mccoll Wealth Management LLC Buys 423 Shares of Amgen Inc. (NASDAQ:AMGN)

Silvia Mccoll Wealth Management LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 13.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,652 shares of the medical research company’s stock after purchasing an additional 423 shares during the quarter. Amgen comprises about 0.8% of Silvia Mccoll Wealth Management LLC’s holdings, making the stock its 29th biggest holding. Silvia Mccoll Wealth Management LLC’s holdings in Amgen were worth $973,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Amgen by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock worth $1,890,769,000 after acquiring an additional 243,720 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Amgen by 14.8% in the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock worth $1,679,625,000 after acquiring an additional 751,947 shares in the last quarter. Norges Bank bought a new position in shares of Amgen in the 4th quarter worth about $1,556,912,000. Finally, California Public Employees Retirement System increased its stake in shares of Amgen by 22.0% in the 4th quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock worth $782,288,000 after acquiring an additional 490,539 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.69% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN traded down $1.44 on Monday, reaching $311.01. 1,768,651 shares of the stock were exchanged, compared to its average volume of 2,783,121. Amgen Inc. has a one year low of $218.44 and a one year high of $329.72. The firm has a market capitalization of $166.84 billion, a PE ratio of 44.36, a PEG ratio of 2.82 and a beta of 0.58. The company’s 50-day simple moving average is $301.56 and its two-hundred day simple moving average is $292.30. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. During the same quarter last year, the business earned $3.98 EPS. The firm’s revenue was up 22.0% compared to the same quarter last year. Analysts expect that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on AMGN shares. Truist Financial reissued a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Royal Bank of Canada increased their price objective on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research report on Friday, June 14th. Mizuho increased their price objective on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $230.00 to $300.00 in a report on Friday, May 3rd. Finally, UBS Group raised their price target on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.